NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapeutics for unmet medical needs in diabetic neuropathy and Alzheimer's disease. The company's lead candidate, NB-01, is a Phase III-ready drug derived from natural sources that has demonstrated promising efficacy and safety in treating diabetic neuropathic pain, addressing both the symptoms and underlying mechanisms of the condition. Approximately 40 to 50 percent of patients with diabetic peripheral neuropathy experience neuropathic pain, yet existing treatments provide limited relief and have significant adverse effects. NeuroBo is also advancing NB-02, its lead Alzheimer’s drug, which is currently in the IND-enabling stage. This drug has been thoroughly studied in preclinical models, targeting key pathways involved in Alzheimer's disease. With the growing prevalence of these conditions among aging populations, NeuroBo Pharmaceuticals aims to provide effective solutions that not only manage symptoms but also modify the diseases themselves.
ANA Therapeutics
Acquisition in 2020
ANA Therapeutics Inc. is a biotechnology company focused on the research and development of niclosamide-based vaccines and therapeutics aimed at treating COVID-19. Founded in 2020 and headquartered in Foster City, California, the company is developing a proprietary formulation of niclosamide, which is designed to help medical practitioners effectively treat patients afflicted with the coronavirus. ANA Therapeutics is actively conducting human clinical trials to evaluate the efficacy of its product, ANA001, which comes in the form of capsules. The company's mission is to address the challenges posed by the coronavirus pandemic and contribute to patient care and recovery.
Gemphire Therapeutics
Acquisition in 2019
Gemphire Therapeutics, a clinical-stage biopharmaceutical company based in Northville, Michigan, focuses on developing and commercializing therapies for dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company's lead product, gemcabene, is an oral medication designed to lower LDL cholesterol in patients who cannot achieve lipid-lowering goals, even while on maximally tolerated statin therapy. Gemphire has completed three Phase IIb clinical trials for gemcabene, targeting conditions such as homozygous familial hypercholesterolemia, hypercholesterolemia, and severe hypertriglyceridemia. Founded in 2014, the company aims to address unmet needs in cardiometabolic disorders and improve patient outcomes. In late 2019, Gemphire Therapeutics was acquired by NeuroBo Pharmaceuticals in a reverse merger transaction.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.